Study by National and Kapodistrian University of Athens Validates Benefits of Smart Meter’s iGlucose® Cellular Diabetes Care Solution

Complete, Accurate and Real-Time Blood Glucose Results Enabled Better Informed Individual Care Recommendations

Smart Meter, an innovative diabetes management data, technology and solutions company, and the National and Kapodistrian University of Athens today announced the results of a study monitoring patient experience and clinician benefits of using the iGlucose® Cellular Diabetes Care Solution. The 2018 study included 66 participants (25 adult females and 41 adult males) of which 10 percent had type 1 diabetes and 90 percent type 2 diabetes.

The clinicians remotely monitored each patient’s real-time data for three months leveraging iGlucose’s cellular technology and found 90% of their patients had a 30% reduction of their average blood glucose levels by the end of the study. By utilizing the iGlucose platform and obtaining real-time data, clinicians found that over 80% of their patients required some form of intervention between appointments. Clinicians also reported that having access to data led to higher quality patient interactions and visits.

From a patient perspective, the vast majority felt comforted knowing their clinicians were viewing their results and trends on a timely basis. 80% of the patients felt they had more control over their diabetes using iGlucose. Cost savings were also experienced by both clinicians and patients due to improved test strip utilization and waste reduction.

“Overall, the study demonstrated that the iGlucose Cellular Diabetes Care Solution could serve as a valuable tool for both patients and clinicians looking to enhance the efficiency and effectiveness of how diabetes is managed today,” said Nikos Tendolouris, Associate Professor of Pathology at National and Kapodistrian University of Athens. “Having complete, accurate and reliable patient data allowed for enhanced clinical care and collaboration during office visits. We weren’t surprised that 67% of the participants indicated that they wanted to continue using iGlucose in the future and another 13% would have continued, if it were available in their Greek language.”

Smart Meter’s cellular iGlucose solution was designed to provide those living with diabetes a convenient and affordable care management solution, while being able to offer healthcare professionals a reliable real-time view of patient data and trends.

“This study validates the effectiveness of iGlucose with both patients and clinicians and why our cellular platform is a critical component to deliver transformative outcomes,” said Cliff McIntosh, CEO of Smart Meter. “Ultimately, iGlucose provided greater patient engagement along with seamless data that supported critical treatment decisions between office visits. More importantly, the vast majority of study participants experienced a reduction in average blood glucose levels and in the end, better data, better care and better outcomes.”

To access the full results of the Smart Meter and National and Kapodistrian University of Athens study, please click here.